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Background: Despite excessive rates of cardiovascular risk factors
such as hypertension, diabetes, and obesity, Afro-Caribbeans have
lower mortality rates from coronary heart disease (CHD) than do
whites. This study evaluated the association of genetic risk markers
previously identiﬁed in whites and CHD in Afro-Caribbeans.
Methods: We studied 537 Afro-Caribbean individuals (178 CHD cases
and 359 controls) who were genotyped for 19 CHD-related single-
nucleotide polymorphisms (SNPs). A genetic risk score (GRS) incor-
porating the 19 SNPs was calculated. These participants were
compared with 1360 white individuals from the Second Northwick
Park Heart Study.Received for publication September 25, 2015. Accepted January 8, 2016.
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Introduction : En depit des taux excessifs des facteurs de risque car-
diovasculaire comme l’hypertension, le diabète et l’obesite, les Afro-
Caribeens ont des taux de mortalite liee aux maladies coronariennes
(MC) plus faibles que les Blancs. La presente etude evaluait l’asso-
ciation entre les marqueurs de risque genetique precedemment
determines chez les Blancs et les MC chez les Afro-Caribeens.
Methodes : Nous avons etudie 537 personnes afro-caribeennes (178
cas de MC et 359 temoins) chez qui le genotypage de 19 poly-
morphismes de nucleotide simple (SNP : single-nucleotide poly-
morphism) lies à la MC avait ete effectue. Nous avons calcule un score
de risque genetique (SRG) qui incorpore les 19 SNP. Nous avonsCoronary heart disease (CHD) is the leading cause of death in
most industrialized countries, with a growing epidemic in low
and middle income countries.1 The development of the dis-
ease depends on a complex interaction between environmental
and genetic factors. Modiﬁable risk factors such as hyperten-
sion, dyslipidemia, diabetes, obesity, and smoking can predict
80%-90% of the risk of CHD in most populations around
the world.2 However, wide differences in CHD incidence and
mortality rates between populations or ethnic groups are not
fully explained by their respective distribution of traditional
cardiovascular risk factors (TCRFs). Indeed, some populations
may have a lower burden of CHD than others despite similar
rates of TCRFs.3,4
The epidemiology of CHD in Afro-Caribbean individuals is
a striking example of the disproportionate relation betweenCHD occurrence and TCRF distribution at the population
level. In the French Caribbean island of Guadeloupe, approxi-
mately 80%-85%of the population is of Afro-Caribbean origin.
Although there are few smokers (15%), there is a high preva-
lence of hypertension (30%), diabetes (10%), and obesity
(23%).5,6 However, observational data indicate lower stan-
dardized mortality rates from CHD in both men (e50%) and
women (e40%) compared with mainland France, which has
one of the lowest incidences of CHD in Europe.7-9 Similar
differences between white and Afro-Caribbean communities
have also been reported in the United Kingdom and remain
unexplained.9,10 The study of such ethnic differences is
important not only for the concerned populations but also for
all populations, because it can provide key information for the
management of CHD and identify new targets for treatment
and preventive strategies.
The lack of a strong correlation between CHD incidence
and TCRFs suggests that genetic variation could lie behind
the interpopulation variability in coronary mortality. In the
past few years, several susceptibility loci for CHD have been
identiﬁed; mostly in white populations, however, no data are
available in Afro-Caribbean populations. Genetic risk scores
(GRSs) could be a valuable tool to assess and compare thedian Cardiovascular Society. This is an open access article under the CC BY
Results: In Afro-Caribbeans, patients with CHD had higher rates of
hypertension (78.7% vs 30.1%), hypercholesterolemia (52.8% vs
15.0%), and diabetes (53.9% vs 14.8%) and were more often men
(64.0% vs 43.7%) and smokers (27.5% vs 13.4%) compared with non-
CHD controls (all P < 0.001). The GRS was higher in Afro-Caribbeans
with CHD than in those without CHD (13.90 vs 13.17; P < 0.001) and
was signiﬁcantly associated with CHD after adjustment for cardiovas-
cular risk factors, with an odds ratio of 1.40 (95% conﬁdence interval,
1.09-1.80) per standard deviation change. There were signiﬁcant dif-
ferences in allelic distributions between the 2 ethnic groups for 14 of
the 19 SNPs. The GRS was substantially lower in Afro-Caribbean con-
trols compared with white controls (13.17 vs 16.59; P < 0.001).
Conclusions: This study demonstrates that a multilocus GRS
composed of 19 SNPs associated with CHD in whites is a strong pre-
dictor of the disease in Afro-Caribbeans. The differences in CHD
occurrence between Afro-Caribbeans and whites might be a result of
signiﬁcant discrepancies in common gene variant distribution.
compare ces participants aux 1360 individus blancs de la deuxième
etude Northwick Park Heart Study.
Resultats : Chez les Afro-Caribeens, les patients atteints de MC
avaient des taux plus eleves d’hypertension (78,7 % vs 30,1 %),
d’hypercholesterolemie (52,8 % vs 15,0 %) et de diabète (53,9 % vs
14,8 %), et etaient plus souvent des hommes (64,0 % vs 43,7 %) et
des fumeurs (27,5 % vs 13,4 %) que les temoins qui n’etaient pas
atteints de MC (tous P < 0,001). Le SRG etait plus eleve chez les Afro-
Caribeens atteints de MC que chez ceux qui n’etaient pas atteints de
MC (13,90 vs 13,17; P < 0,001) et signiﬁcativement associe aux MC
après l’ajustement des facteurs de risque cardiovasculaire, et montrait
un ratio d’incidence approche de 1,40 (intervalle de conﬁance à 95 %,
1,09-1,80) par changement d’ecart type. Les distributions des
frequences alleliques de 14 des 19 SNP montraient des differences
signiﬁcatives entre les 2 groupes ethniques. Le SRG etait sub-
stantiellement plus bas chez les temoins afro-caribeens que chez les
temoins blancs (13,17 vs 16,59; P < 0,001).
Conclusions : Cette etude demontre que le SRG multilocus compose
de 19 SNP qui est associe aux MC chez les Blancs est un fort
predicteur de la maladie chez les Afro-Caribeens. Les differences dans
la survenue des MC entre les Afro-Caribeens et les Blancs pourraient
resulter des divergences importantes dans la distribution des variants
genetiques frequents.
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Ethnic Differences in Coronary Heart Diseasegenetic susceptibility for complex diseases in different ethnic
groups, because they summarize the potential genetic
inﬂuences across multiple loci into a single quantitative
parameter.11 In this study, we aimed to describe in Afro-
Caribbeans with and without CHD, the allelic distribution
of 19 CHD-related single nucleotide polymorphisms (SNPs)
that have been reported in white studies. We also tested the
hypothesis that the differences in genetic susceptibility for
CHD assessed by a GRS could contribute to the disparity in
CHD occurrence between whites and Afro-Caribbeans.Methods
Study populations, CHD status, and TCRF deﬁnition
The Afro-Caribbean participants were recruited from the
island of Guadeloupe, a French Caribbean region with a wide
availability of health services and easy access to medical care
regardless of income. All participants were Afro-Caribbeans.
The ethnic origin was determined when the patient deﬁned
him or herself and 2 ﬁrst-degree relatives as Afro-Caribbean.
Cases were selected from the Department of Cardiology at the
University Hospital of Pointe-à-Pitre. Patients were eligible if
they had a documented history of previous acute myocardial
infarction according to the World Health Organization criteria
or coronary bypass surgery (or both) or coronary angioplasty.
Control participants were selected from a public health centre
on the same island and who had no suspicion or history of
cardiovascular disease. TCRFs were determined using the same
deﬁnition in cases and controls. Participants were considered as
having hypertension if they had a history of hypertension or
were prescribed antihypertensive therapy. Similarly, they were
considered as having diabetes or hypercholesterolemia if they
had a history of diabetes or hypercholesterolemia or were
prescribed hypoglycemic agents (including insulin) or
lipid-lowering therapy, respectively. Participants wereconsidered to be current smokers if they were regularly smoking
more than 1 cigarette per day at the time of inclusion. Bodymass
index (BMI) was calculated as weight/height2 (kg/m2), and
obesity was determined by a BMI 30 kg/m2. All participants
gave their written informed consent to participate in the study,
which received the approval of the inter-regional ethics
committee (Sud-Ouest/Outre-Mer III, France).
The white sample used was from the Second Northwick
ParkHeart Study (NPHSII) and has already been described.12
Brieﬂy, 3052 middle-aged men (50-64 years of age) with no
previous history of cardiovascular disease were recruited from
9 general practices in the United Kingdom. The study started
in 1989, and incident cases of acute or silent myocardial
infarction and coronary surgery were recorded during a
median of 13.5 years of follow-up. All participants gave
written informed consent, and the study was approved by the
National Health Service Health Research Authority Research
Ethics Committee LondoneCentral.Genotyping and genetic scores calculation
Genotyping was performed using published TaqMan
(Applied Biosciences/Life Technologies, Grand Island, NY),
and KASPar (KBioscience, Hertfordshire, UK) technologies.
We selected 19 SNPs that were associated with CHD in
whites in genome wide association studies (GWASs) or meta-
analysis of candidate gene association studies.13,14 A non-
weighted GRS was calculated for each individual by summing
the number of risk alleles at each locus (0 if risk allele was
absent and 1 if heterozygote or 2 if homozygote for the risk
allele). A weighted score was calculated by multiplying the
number of risk alleles at each locus by the corresponding b
coefﬁcient from the CARDIoGRAMplusC4D meta-analysis
data (or the CARDIoGRAM GWAS if this was not avail-
able). Data on coronary artery disease/myocardial infarction
were contributed by CARDIoGRAMplusC4D investigators
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Regarding the nonweighted score, we assumed that all SNPs
were acting in an additive manner. We previously reported
that a weighted gene score including these SNPs was associ-
ated with CHD in the NPHSII cohort.15
We also calculated (using the same method) a 14-SNP
GRS after exclusion of SNPs in loci at which the P value
for association with CHD was < 0.01 in either the
CARDIoGRAM GWAS or CARDIoGRAMplusC4D meta-
analysis.14,16 The SNPs included in the scores and their
estimates are presented in Table 1.
Statistical analysis
Only participants with complete data regarding TCRFs
and genotype were included for the analysis. In the Afro-
Caribbean sample, we randomly selected 2 controls for each
case. A c2 test was used to assess whether each SNP was in
Hardy-Weinberg equilibrium. The GRSs were considered as
continuous variables. We used logistic regression to assess the
association of GRSs and TCRFs with CHD as a binary
dependant variable. To evaluate the predictive value of GRS
in Afro-Caribbeans, we used the receiver-operating charac-
teristic curve analysis and calculated the area under the curve
from logistic models adjusted by age and sex. IBM SPSS
Statistics, version 21 (SPSS, Chicago, IL) was used for
analysis. All tests were 2 sided and P values of < 0.05 were
considered signiﬁcant.Results
In the Afro-Caribbean sample, the analysis included a total
of 178 cases and 359 controls. Table 2 shows the character-
istics of the participants. Patients with CHD had higher rates
of hypertension, diabetes, and hypercholesterolemia and were
more often men and smokers than were controls. TheTable 1. SNPs included in the genetic risk scores (GRS14 and GRS19) and
SNP Chromosome Gene/locus
SNP location or
amino acid change R
rs4341 17q23 ACE Intergenic G
rs662799* 11q23 APOA5 Promoter Variant G
rs1042031 2p23-24 APOB E4181K A
rs429358* 19q13.2 APOE C112R C
rs7412* 19q13.2 APOE C158R C
rs10757274* 9p21 CDKN2A/CDKN2B Intergenic G
rs599839* 1p13.3 CELSR2/PSRC1/SORT1 Intergenic A
rs708272 16q21 CETP Intronic C
rs1746048* 10q11.2 CXCL12 Intergenic C
rs7025486* 9q33 DAB2IP Intergenic A
rs10455872* 6q26 LPA Intergenic G
rs3798220* 6q26 LPA I1891M C
rs1801177* 8p22 LPL D36N A
rs328* 8p22 LPL S474X C
rs17465637* 1q41 MIA3 Intergenic C
rs9818870* 3q23.3 MRAS Intergenic T
rs1799983 7q35-36 NOS3 D298E T
rs11591147* 1p32.3 PSCK9 R46L G
rs17228212 15q22 SMAD3 Intergenic C
The APOA5 promoter variant has been shown to be functional.19 All SNPs we
OR, odds ratio; SNP, single nucleotide polymorphism.
* SNPs that were selected for the 14-SNP-GRS (GRS14) construction.prevalence of obesity and the mean BMI did not differ be-
tween cases and controls.
For the 19 genotyped SNPs, call rates ranged from
94%-98%. All SNPs were in Hardy-Weinberg equilibrium.
The risk allele frequency of rs599839 (CELSR2/PSRC1/
SORT1) and rs1746048 (CXCL12) was higher in cases than
in controls (0.35 vs 0.25; P ¼ 0.01 and 0.63 vs 0.53; P ¼
0.03, respectively). The difference was nearly signiﬁcant for
rs17465637 (MIA3): 0.31 in cases vs 0.24 in controls (P ¼
0.08). Full details are available in Supplemental Table S1.
Differences in common CHD-related SNPs between
Afro-Caribbeans and whites
Table 3 shows the risk allele frequencies of the 19 SNPs in
white and Afro-Caribbean participants without CHD. For
rs11591147, rs1801177, and rs3798220, comparisons were
not meaningful because the minor allele frequencies were very
low or null in both groups. For the remaining SNPs, there
were signiﬁcant differences in allelic distributions between the
2 ethnic groups, with the exception of rs7412 (APOE) and
rs1042031 (APOB). Both the mean nonweighted GRS19 and
GRS14 were lower in Afro-Caribbean controls than in white
controls: 13.17 vs 16.59 (P < 10100) and 9.69 vs 12.76
(P < 10100), respectively (Table 3). Histograms representing
the distribution of the nonweighted GRS in white and
Afro-Caribbean controls are shown in Supplemental
Figure S1.
Association between GRS and CHD in Afro-Caribbeans
The weighted and the nonweighted GRS19 were signiﬁ-
cantly higher in Afro-Caribbeans with CHD than in those
without CHD: 13.90 ( 2.07) vs 13.17( 2.10); P ¼ 1.6 
104 and 1.74 ( 0.24) vs 1.68 ( 0.20); P ¼ 0.01,
respectively. Results were similar with the weighted and the
nonweighted GRS14 (Supplemental Table S2).their published estimates
Alleles Published
OR Referenceisk/reference
/C 1.01 Schunkert et al.16
/A 1.1 CARDIoGRAMplusC4D Consortium et al.14
/G 1.01 CARDIoGRAMplusC4D Consortium et al.14
/T 1.25 Bennett et al.17
/T 1.06 Bennett et al.17
/A 1.23 CARDIoGRAMplusC4D Consortium et al.14
/G 1.11 CARDIoGRAMplusC4D Consortium et al.14
/T 1.04 Schunkert et al.16
/T 1.07 CARDIoGRAMplusC4D Consortium et al.14
/G 1.04 CARDIoGRAMplusC4D Consortium et al.14
/A 1.32 Schunkert et al.16
/T 1.28 Schunkert et al.16
/G 1.09 CARDIoGRAMplusC4D Consortium et al.14
/G 1.1 CARDIoGRAMplusC4D Consortium et al.14
/A 1.14 Schunkert et al.16
/C 1.07 CARDIoGRAMplusC4D Consortium et al.14
/G 1.0 CARDIoGRAMplusC4D Consortium et al.14
/T 1.39 Benn et al.18
/T 1.01 CARDIoGRAMplusC4D Consortium et al.14
re included in the 19-SNP gene score (GRS19).
Table 2. Characteristics of the 537 Afro-Caribbean participants
Cases
(n ¼ 178)
Controls
(n ¼ 359) P value
Age, y 63.20
( 10.50)
51.66
( 13.54)
< 1  105
Male sex, % 64.0 43.7 < 1  105
Hypertension, % 78.7 30.1 < 1  105
Hypercholesterolemia, % 52.8 15.0 < 1  105
Diabetes, % 53.9 14.8 < 1  105
Current smokers, % 27.5 13.4 < 1  105
BMI 27.41
( 4.86)
27.15
( 5.62)
0.535
Obesity (BMI > 30
kg/m2), %
23.9 28.9 0.224
Data were available for all participants and are presented as mean ( SD)
or percent. Categorical variables were compared using the c2 test. The student
t test was used for comparison between continuous variables.
BMI, body mass index.
Table 4. Association between cardiovascular risk factors and GRS
with CHD in Afro-Caribbeans
Multivariate logistic regression for CHD
OR 95% CI P value
Age 1.06 (1.03-1.08) < 1  105
Male sex 3.09 (1.84-5.19) 2  105
Hypertension 4.30 (2.49-7.26) < 1  105
Diabetes 2.13 (1.23-3.68) 7  103
Hypercholesterolemia 3.45 (2.08-5.73) < 1  105
Smoking 3.06 (1.64-5.71) 5  104
Nonweighted GRS19 1.40 (1.09-1.80) 8  103
ORs are expressed per 1 standard deviation change.
CHD, coronary heart disease; CI, conﬁdence interval; GRS, genetic risk
score; OR, odds ratio.
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percholesterolemia, and smoking, the association between
GRS and CHD was not signiﬁcant for the weighted GRS19,
nearly signiﬁcant for the weighted GRS14, and highly sig-
niﬁcant for both nonweighted GRSs, with odds ratios (ORs)
of 1.40 (95% conﬁdence interval [CI], 1.09-1.80; P ¼ 0.008)
for GRS19 and 1.43 (95% CI, 1.12-1.83; P ¼ 0.004) for
GRS14 (Tables 4 and 5). In the model incorporating the
TCRFs, analysis between subsequent quintiles of the non-
weighted GRS19 showed a stepwise increase in the risk of
CHD from the ﬁrst to ﬁfth quintiles. Participants in the top
quintile (11.7% of the controls) had an OR of 2.41 (95% CI,
1.17-4.95; P ¼ 0.02) compared with those in the bottom
quintile (38.2% of the controls). Results were similar when
using the nonweighted GRS14 (Fig. 1).
Figure 2 shows the receiver operating characteristic curve
area under the curve (AUC) for the logistic regression modelsTable 3. Risk allele frequencies of the 19 SNPs and GRSs in Afro-Caribbean
SNP Gene
Afro-Caribbeans without CHD
RAF
rs4341 ACE 0.6
rs662799 APOA5 0.13
rs1042031 APOB 0.15
rs429358 APOE 0.23
rs7412 APOE 0.93
rs10757274 CDKN2A/CDKN2B 0.21
rs599839 CELSR2/PSRC1/SORT1 0.25
rs708272 CETP 0.76
rs1746048 C  CL12 0.53
rs7025486 DAB2IP 0.32
rs10455872 LPA 0.01
rs3798220 LPA 0.01
rs1801177 LPL 0.001
rs328 LPL 0.94
rs17465637 MIA3 0.24
rs9818870 MRAS 0.08
rs1799983 NOS3 0.12
rs11591147 PSCK9 1.00
rs17228212 SMAD3 0.12
Nonweighted GRS19 (SD) 13.17 ( 2.10)
Nonweighted GRS14 (SD) 9.69 ( 1.70)
For white participants, RAFs are reported from the NPHSII cohort.
CHD, coronary heart disease; GRS, genetic risk score; NA, not available; NPH
standard deviation; SNP, single nucleotide polymorphism.incorporating TCRFs alone or with addition of the non-
weighted GRS14. All models were adjusted for age. The
addition of the GRS appeared to slightly increase the AUC
from the model incorporating only TCRFs, but the difference
was not signiﬁcant: P ¼ 0.09 for GRS14 and P ¼ 0.2 for
GRS19 (Supplemental Fig. S2).Association between GRS and TCRFs in Afro-
Caribbeans
We compared the mean GRS19 in the CHD and non-
CHD participants separately according to the presence or
absence of each TCRF. In the non-CHD group, both the
weighted and the nonweighted GRS19 did not differ in pa-
tients with diabetes and those without diabetes, and results
were similar when hypertension, hypercholesterolemia, or
smoking was considered (Supplemental Table S3). In the
CHD group, the weighted and nonweighted GRS19 were not
associated with hypertension, smoking, or diabetes, but both
were signiﬁcantly higher in patients with hypercholesterolemiacontrols compared with white controls
(n ¼ 359) Whites without CHD (n ¼ 1214)
P valueRAF
0.52 8  103
0.06 1  105
0.18 0.19
0.17 0.01
0.91 0.23
0.48 8.19  1020
0.78 3  1077
0.56 1  1011
0.86 1  1040
0.26 0.03
0.07 1  105
0.02 0.21
0.01 NA
0.90 0.02
0.71 2  1057
0.16 1  104
0.33 8  1015
0.99 NA
0.31 9  1013
16.59 ( 2.20) < 1  10100
12.76 ( 1.69) < 1  10100
SII, Second Northwick Park Heart Study; RAF, risk allele frequency; SD,
Table 5. Predictive value of GRSs in Afro-Caribbeans after adjustment
with TCRFs
Multivariate logistic regression for CHD (N ¼ 537)
OR 95% CI P value
NW_GRS19 1.40 (1.09-1.80) 8  103
W_GRS19 1.20 (0.94-1.53) 0.14
NW_GRS14 1.43 (1.12-1.83) 4  103
W_GRS14 1.25 (0.99-1.59) 0.06
ORs are expressed per 1 standard deviation change and were calculated
from model incorporating each GRS, age, sex, hypertension, diabetes, hy-
percholesterolemia, and smoking.
CI, conﬁdence interval; GRS, genetic risk score; NW, nonweighted; OR,
odds ratio; TCRFs, traditional cardiovascular risk factors; W, weighted.
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(Supplemental Table S4).
Assessment of the risk of CHD in Afro-Caribbeans and
whites based on the GRS
To compare the strength of the association between the
GRSs and CHD in Afro-Caribbeans and whites, we calculated
the OR of weighted and nonweighted GRS19 and GRS14 in
models incorporating TCRFs in both ethnic groups. For this
analysis, the Afro-Caribbean women (n ¼ 266) were excluded
because the NPHSII cohort included only men. As shown in
Table 6, the ORs of the GRSs were similar in Afro-Caribbeans
and whites.
The mean nonweighted GRS19 and nonweighted GRS14
were signiﬁcantly lower in Afro-Caribbean men than in
whites: 12.88 ( 2.00) vs 16.59 ( 2.20) and 9.53 ( 1.66)
vs 12.76 ( 1.69) (P < 10100for all). Based on these
observed differences in GRS and on the predictions from the
logistic models incorporating risk factors (age, hypertension,1
1.2 1.33
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Figure 1. Association between genetic risk score (GRS)19 (A) and GRS14
Caribbeans. Each quintile from the ﬁrst (Q1) to the ﬁfth (Q5) are shown alo
conﬁdence interval are plotted on the y axis and were calculated from logi
pertension, diabetes, hypercholesterolemia, and smoking. First quintile: refe
0.60; fourth quintile, P¼ 0.04; ﬁfth quintile, P¼ 0.02. For GRS14: second qu
quintile, P ¼ 0.02.diabetes, hypercholesterolemia, and smoking), the expected
risk for CHD would be reduced by 54% or 44% in Afro-
Caribbeans compared with whites depending on the use of
the GRS19 or the GRS14, respectively.Discussion
In this study, we investigated the association between 19
selected CHD genetic risk markers, TCRFs, and CHD in
Afro-Caribbeans. We also assessed if the differences in risk
allele frequency between Afro-Caribbeans and whites are a
potential explanation for the lower occurrence of CHD re-
ported in Afro-Caribbeans.
We found that a GRS representing the cumulative effect of
19 SNPs was signiﬁcantly associated with CHD in Afro-
Caribbeans. Moreover, the contribution of the GRS to
CHD prediction was high and, based on the logistic regres-
sion analysis, provided complementary information beyond
TCRFs. There were marked differences in the allelic distri-
butions of the 19 SNPs between whites and Afro-Caribbeans,
and both the weighted and nonweighted GRSs were sub-
stantially and signiﬁcantly lower in Afro-Caribbeans than in
whites, suggesting that the lower CHD risk seen in Afro-
Caribbeans may result in part from a lower prevalence of
these CHD risk alleles.
Association of TCRFs with CHD in Afro-Caribbeans
Observational studies have documented a lower mortality
rate from CHD in Afro-Caribbeans living in the Caribbean as
well as in those living in Europe.7,10,20 However, few studies
have investigated the association between TCRFs and CHD
in this population or examined the reason for the low mor-
tality from CHD in Afro-Caribbeans despite a high prevalence
of risk factors such as diabetes, hypertension, and obesity seen1
1.16
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4
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6
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O
dd
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(B) divided into quintiles and coronary heart disease (CHD) in Afro-
ng the x axis. Odds ratios with the error bars representing the 95%
stic regression models incorporating nonweighted GRS, age, sex, hy-
rence group. For GRS19: second quintile, P ¼ 0.60; third quintile, P ¼
intile, P¼ 0.70; third quintile, P¼ 0.17; fourth quintile, P ¼ 0.06; ﬁfth
Figure 2. Incremental contribution of genetic risk score (GRS) to
coronary heart disease (CHD) discrimination in Afro-Caribbeans (n ¼
537). Predictions are based on logistic regression models incorpo-
rating traditional cardiovascular risk factors (TCRFs) (age, sex, hy-
percholesterolemia, diabetes, hypertension, and smoking) alone or
with the addition of the nonweighted 14 single nucleotide poly-
morphism (SNP) GRSs. The area under the curve (AUC) measures the
ability of the model to discriminate between individuals with CHD and
those without CHD.
Lariﬂa et al. 983
Ethnic Differences in Coronary Heart Diseasein the general population.9,21,22 Some studies have suggested a
more favourable lipid proﬁle, even in the context of insulin
resistance, compared with whites and also a lower impact of
diabetes on CHD in Afro-Caribbeans than in whites or South
Asians.21,23 Conversely, in the INTERHEART case-control
study involving 52 countries around the world, the ORs for
the association of the major TCRFs with CHD did not vary
appreciably among ethnic groups.2 However, no Afro-
Caribbean sample was included in this study. In our study,
the prevalence of TCRFs in the control group were in line
with those previously reported in the general population,
indicating that our sample was representative of this popula-
tion.5,6 In the Afro-Caribbean cases, the presence of all major
risk factors was 2-3.5 times higher than in the controls except
for obesity. This ﬁnding does not support the hypothesis thatTable 6. Predictive values of GRSs in Afro-Caribbeans and whites males aft
Afro-Caribbeans
OR 95% CI P valu
NW_GRS19 1.62 (1.16-2.27) 4  10
W_GRS19 1.32 (0.96-1.81) 0.08
NW_GRS14 1.42 (1.03-1.95) 0.03
W_GRS14 1.38 (1.01-1.88) 0.04
ORs are expressed per 1 standard deviation change and were calculated from mod
and smoking in both ethnic groups. In the Afro-Caribbean sample, we considered on
for GRS19 and n ¼ 1607 for GRS14).
CI, conﬁdence interval; GRS, genetic risk score; NPHSII, Second Northwick Pa lower impact of TCRFs could fully explain the low rate of
CHD in Afro-Caribbeans and reinforces the need for an
alternative or complementary explanation.Gene variant for CHD in Afro-Caribbeans
To the best of our knowledge, this is the ﬁrst study on the
allelic distribution of these CHD-related SNPs in Afro-
Caribbeans. For most SNPs, the allelic distribution was
markedly different than in whites and similar to or approxi-
mately midway between that of the HapMap samples from
the Yoruba of Nigeria and that of African Americans
(Supplemental Table S5). Only 2 SNPs, rs599839 (CELSR2/
PSRC1/SORT1) and rs1746048 (CXCL12), were statistically
associated with CHD. However, it is highly likely that a lack
of power because of our sample size would mask other po-
tential associations. The direction of the association was the
same as in previous GWASs performed in whites. Although it
is likely that most of the reported GWAS-lead SNPs are not
the causal variant but are only markers in linkage disequilib-
rium (LD) with the functional variant, 11 of the variants
included in this SNP panel directly affect the function or level
of the cognate protein (eg, the common APOE variant).
Nonetheless, given the likely differences in LD structure
between the 2 ethnic groups, it is possible that some of the
selected SNPs associated with CHD in whites would be a
poor marker (because of low LD with the causal variation) in
Afro-Caribbeans.Association of the GRSs with CHD in Afro-Caribbeans
The weighted and nonweighted GRSs were signiﬁcantly
higher in Afro-Caribbean participants with CHD than in
controls, even after adjustment for TCRFs. The nonweighted
scores (GRS19 and GRS14) were strong predictors of CHD,
with a 40% increase in CHD risk per standard deviation.
Participants in the highest quintile of GRS had a nearly 2.5-
fold higher risk of CHD compared with those in the lowest
quintile. The weighted GRSs calculated on the basis of the
risk estimates reported in Europeans appear to be less pre-
dictive of CHD than are the nonweighted GRSs. This is likely
a consequence of differing LD patterns, in which some of the
lead SNPs are in much weaker LD with the causal SNP in
Afro-Caribbeans compared with whites. This will vary from
SNP to SNP depending on the LD pattern at each risk locus.
Weighting gene scores using b effects is used to reﬂect the
relative contribution each locus has to risk (as opposed to
treating them as having the same effect); however, if someer adjustment with TCRFs
Whites (NPHSII)
e OR 95% CI P value
3 1.27 (1.06-1.51) 9  103
1.33 (1.11-1.60) 2.3  103
1.40 (1.19-1.66) 5.3  105
1.42 (1.20-1.67) 3.3  105
el incorporating each GRS, age, hypertension, diabetes, hypercholesterolemia,
ly men (n ¼ 271) because the NPHSII cohort included only men (n ¼ 1360
ark Heart Study; NW, nonweighted; OR, odds ratio; W, weighted.
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reﬂected and can result in a poorly ﬁtting model.
Usefulness of the GRS to assess interpopulation
variation in CHD occurrence
Although being highly associated with CHD in Afro-
Caribbeans, the GRSs were markedly lower in Afro-
Caribbeans compared with whites. These 2 ﬁndings support
our hypothesis that the differences in genetic susceptibility
between the 2 populations could be an important contributor
to the lower mortality from CHD in Afro-Caribbeans. It is
assumed that 40%-60% of the risk of CHD is heritable,24 and
most modiﬁable TCRFs (such as hypertension, dyslipidemia,
diabetes, or obesity) are highly heritable, making a genetic
approach an attractive way to assess the occurrence of this
complex disease. However, the SNPs identiﬁed by GWASs
confer individually a modest increase in relative risk (average
OR of 1.15-1.20). Thus, the summation of each SNP effect in
a single variable called the GRS has the ability to capture a
larger part of the genetic susceptibility to the disease. Different
GRS constructions have been used in many studies, but the
GRS usually added only modestly to the disease prediction
based on TCRF models.11,25 In this study, we used the GRS
to assess CHD risk within the Afro-Caribbean population but
also through a comparison between 2 populations of different
ancestry. Published works using this approach at an inter-
population level are scarce. Our data indicate that based on
the observed differences in GRS between the 2 ethnic groups,
the expected risk for CHD would be 44%-54% lower in Afro-
Caribbeans than in whites, which is comparable to the 50%
lower CHD mortality in these individuals reported in France
and the United Kingdom.7,10 Although we have demonstrated
the potential utility of the nonweighted GRS within the Afro-
Caribbean population, the data demonstrate that the
published weighting from the white population reduces the
predictive value of the GRS. This suggests that the weighting
of SNPs for CHD risk cannot be directly transferred between
different ethnic groups. To improve the clinical utility of the
GRS, ethnic-speciﬁc weightings, obtained from large
population-based cohorts, will be needed. Conﬁrmatory
studies are necessary to prove the utility of this tool to assess
the disparity in CHD risk between populations, in particular
when they are not fully explained by the distribution of
TCRFs.
Interestingly, despite a genetic architecture similar to that
of Afro-Caribbeans, African Americans have higher rates of
CHD than Americans of European ancestry. In fact, in the
ﬁrst half of the 20th century, CHD mortality was lower in
Afro-Americans than in European Americans but has declined
less rapidly among African Americans than among European
Americans and now are higher in African Americans than in
other ethnic groups in the United States.26 The high preva-
lence of most CRFs in African Americans and the impact of a
low socioeconomic status on heath and access to care are well-
known confounding factors that could have overwhelmed the
potential effects of a lower genetic burden in this population.
Our study has some limitations. The size of our Afro-
Caribbean sample may have been insufﬁcient to detect all
potential associations between individual SNPs and CHD,
and we cannot rule out that some SNPs with lower or evensimilar size effect as those highlighted in this study were not
detectable in this sample. We assessed the difference in genetic
burden between whites and Afro-Caribbeans using a con-
structed GRS and assuming that the risk for CHD was linked
to the same set of genetic factors in both populations.
Moreover, our 19-SNP selection represented only part of the
list of the more robustly CHD-associated SNPs that comprise
at least 46 loci to date,14 and no GWAS had been performed
in Afro-Caribbeans. Taken together, these limitations make it
possible that the gap in genetic burden between Afro-
Caribbeans and whites could have been different with a
wider GRS. However, to date, GWASs performed in African
Americans, who have a genetic architecture similar to that of
the Afro-Caribbean participants examined here, found no
novel variant with reproducible association with CHD that
had not been described in whites.27,28
Hence, the high discrimination ability of the GRS in Afro-
Caribbeans leads us to believe that a signiﬁcant part of the
CHD risk information has been captured with this approach
in our study. We believe that the main limits of our study can
be overcome in a future work testing a wider GRS in a larger
multiethnic study designed to conﬁrm the potential of this
original approach. If conﬁrmed, this approach could be of
clinical and epidemiologic interest in assessing the risk for
CHD in different populations in addition to the traditional
risk factor assessment. In this study, the GRS was considered
as a complementary tool rather than an alternative to tradi-
tional cardiovascular risk factor assessment. Because of the
limited size of our sample and the lack of speciﬁc estimates for
Afro-Caribbeans, we did not focus on the incremental value of
the GRS in this study. Although incorporating a gene score
test into a patient’s clinical risk assessment using conventional
risk factors would have cost implications, such costs would be
minimal because the genotyping of the 19 SNPs used here can
easily and cheaply be carried out using a saliva sample.Conclusions
This study demonstrates that a multilocus GRS composed
of SNPs associated with CHD in whites is a strong predictor
of the disease in Afro-Caribbeans. The genetic burden for
CHD identiﬁed by this 19-SNPs GRS was signiﬁcantly lower
in Afro-Caribbeans than in whites and could be a major
contributor to the disparity in CHD mortality between these
2 populations. Further work is needed to conﬁrm these
ﬁndings and to identify more extensively the genetic variants
that contribute to CHD in Afro-Caribbeans.Disclosures
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